STUDY QUESTION: What is the impact of the EuroNet-PHL-C2 treatment for boys with classical Hodgkin lymphoma (cHL) on semen parameters? SUMMARY ANSWER: More than half of the patients (52%, n = 16/31) had oligozoospermia or azoospermia at 2 years from cHL diagnosis; particularly boys treated for advanced-stage cHL had low sperm counts and motility. WHAT IS KNOWN ALREADY: Chemotherapy and radiotherapy to the inguinal region or testes can impair spermatogenesis and result in reduced fertility. The EuroNet-PHL-C2 trial aims to minimize radiotherapy in standard childhood cHL treatment, by intensifying chemotherapy. The present study aims to assess the (gonadotoxic) impact of this treatment protocol on semen parameters and reproductive hormones in boys aged ≤18 years. STUDY DESIGN, SIZE, DURATION: This international, prospective, multi-centre cohort study was an add-on study to the randomized phase-3 EuroNet-PHL-C2 trial, where the efficacy of standard cHL treatment with OEPA-COPDAC-28 (OEPA: vincristine, etoposide, prednisone, and doxorubicin; COPDAC-28: cyclophosphamide, vincristine, prednisone, and dacarbazine) was compared to intensified OEPA-DECOPDAC-21 chemotherapy (DECOPDAC-21: COPDAC with additional doxorubicin and etoposide and 25% more cyclophosphamide). Patients were recruited between January 2017 and September 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS: Eligibility criteria included male patients, diagnosed with classical HL before or at the age of 18 years, and treated according to the EuroNet-PHL-C2 protocol in any of the 18 participating sites in the Netherlands, Germany, Belgium, Czech Republic, and Austria. Sperm parameters (sperm concentration, progressive motility, sperm volume, and calculated total motile sperm count) were assessed at diagnosis and 2 years after diagnosis in (post)pubertal boys. Laboratory measurements (serum follicle-stimulating hormone (FSH) and inhibin B) were performed in samples drawn at diagnosis, during treatment (2-3 times), and at 2 years post-diagnosis, and (age-adjusted) analyses were conducted separately for pre-pubertal and (post)pubertal boys. Outcomes were compared between the treatment levels (TL1, TL2, and TL3) and consolidation treatment schemes (COPDAC-28 and DECOPDAC-21). MAIN RESULTS AND THE ROLE OF CHANCE: In total, 101 boys were included in the present analysis: 73 were (post)pubertal (median age 15.4 years, (IQR 14.4; 16.6), 10 TL1, 29 TL2, 34 TL3, 62% of TL2/3 patients received COPDAC-28) and 28 boys were pre-pubertal (median age 9.6 years (IQR 6.6; 11.4), 4 TL1, 7 TL2, 17 TL3, 38% of TL2/3 patients received COPDAC-28). The study included six boys who had received pelvic radiotherapy; none were irradiated in the inguinal or testicular area. At diagnosis, 48 (post)pubertal boys delivered semen for cryopreservation; 19 (40%) semen samples were oligospermic and 4 (8%) were azoospermic. Low sperm concentration (<15 mil/ml) appeared to be related to the HL disease itself, with a higher prevalence in boys who presented with B symptoms (76% vs 26%, aOR 2.3 (95% CI 1.0; 3.8), P = 0.001) compared to those without such symptoms. At 2 -years post-diagnosis, 31 boys provided semen samples for analysis, of whom 12 (39%) boys had oligozoospermia and 4 (13%) had azoospermia, while 22 boys (71%) had low total motile sperm counts (TMSC) (<20 mil). Specifically, the eight boys in the TL3 group treated with DECOPDAC-21 consolidation had low sperm counts and low progressive motility after 2 years (i.e. median sperm count 1.4 mil/ml (IQR <0.1; 5.3), n = 7 (88%), low sperm concentration, low median progressive motility 16.5% (IQR 0.0; 51.2), respectively). Age-adjusted serum FSH levels were significantly raised and inhibin B levels (and inhibin B:FSH ratios) were decreased during chemotherapy in (post)pubertal boys, with subsequent normalization in 80% (for FSH) and 60% (for inhibin B) of boys after 2 years. Only 4 out of the 14 (post)pubertal boys (29%) with low sperm concentrations after 2 years had elevated FSH (>7.6 IU/l), while 7 (50%) had low inhibin B levels (<100 ng/l). In pre-pubertal boys, reproductive hormones were low overall and remained relatively stable during chemotherapy. LIMITATIONS, REASONS FOR CAUTION: The present analyses included sperm and laboratory measurements up to 2 years post-diagnosis. Long-term reproductive outcomes and potential recovery of spermatogenesis remain unknown, while recovery was reported up to 5- or even 10-year post-chemotherapy in previous studies.Boys who were pre-pubertal at diagnosis were still too young and/or physically not able to deliver semen after 2 years and we could not assess a potential difference in gonadotoxicity according to pubertal state at the time of treatment. Overall, the statistical power of the analyses on sperm concentration and quality after 2 years was limited. WIDER IMPLICATIONS OF THE FINDINGS: Results of the semen analyses conducted among the 31 boys who had provided a semen sample at 2 years post-treatment were generally poor. However, additional long-term and adequately powered data are crucial to assess the potential recovery and clinical impact on fertility. The participating boys will be invited to deliver a semen sample after 5 years. Until these data become available, benefits of intensified chemotherapy in cHL treatment to reduce radiotherapy and lower risk for development of secondary tumours should be carefully weighed against potentially increased risk of other late effects, such as diminished fertility due to the increased chemotherapy burden. Boys with newly diagnosed cHL should be encouraged to deliver sperm for cryopreservation whenever possible. However, patients and clinicians should also realize that the overall state of disease and inflammatory milieu of cHL can negatively affect sperm quality and thereby reduce chance of successful fertility preservation. Furthermore, the measurement of FSH and inhibin B appears to be of low value in predicting low sperm quality at two years from cHL treatment. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the Dutch charity foundation KiKa (project 257) that funds research on all forms of childhood cancer. C.M.-K., D.K., W.H.W., D.H., MC, A.U., and A.B. were involved in the development of the EuroNet-PHL-C2 regimen. The other authors declare no potential conflict of interest. TRIAL REGISTRATION NUMBER: N/A.

Cancer Center Amsterdam Treament and quality of life Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands

Department of Epidemiology and Data Science Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands

Department of Haematology Oncology Erasmus MC Sophia Children's Hospital Rotterdam The Netherlands

Department of Haematology Oncology Royal Hospital for Sick Children Edinburgh UK

Department of Paediatric Haemato Oncology Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands

Department of Pediatric Hematology and Oncology Universitätsklinikum Giessen und Marburg GmbH Standort Giessen Zentrum für Kinderheilkunde und Jugendmedizin Giessen Germany

Department of Pediatric Hematology and Oncology University Hospital Motol and 2nd Medical Faculty Charles University Prague 5 Czech Republic

Department of Reproductive Medicine and Gynecology University Medical Center Utrecht Utrecht The Netherlands

Department of Urology University Medical Centre Utrecht Utrecht The Netherlands

Institut für Medizinische Informatik Statistik und Epidemiologie Universität Leipzig Leipzig Germany

Paediatric Haemato Oncology University Hospitals of Leuven Leuven Belgium

Pediatric Hematology and Oncology St Anna Children's Hospital Medical University of Vienna Wien Austria

Pediatric Oncology Cancer Center Amsterdam Emma Children's Hospital Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands

Zobrazit více v PubMed

Amirjannati N, Sadeghi M, Hosseini Jadda SH, Ranjbar F, Kamali K, Akhondi MA.. Evaluation of semen quality in patients with malignancies referred for sperm banking before cancer treatment. Andrologia 2011;43:317–320. PubMed

Anderson RA, Wallace EM, Groome NP, Bellis AJ, Wu FCW.. Physiological relationships between inhibin B, follicle stimulating hormone secretion and spermatogenesis in normal men and response to gonadotrophin suppression by exogenous testosterone. Hum Reprod 1997;12:746–751. PubMed

Andersson AM, Skakkebaek NE.. Serum inhibin B levels during male childhood and puberty. Mol Cell Endocrinol 2001;180:103–107. PubMed

Andersson AM, Petersen JH, Jørgensen N, Jensen TK, Skakkebaek NE.. Serum inhibin B and follicle-stimulating hormone levels as tools in the evaluation of infertile men: significance of adequate reference values from proven fertile men. J Clin Endocrinol Metab 2004;89:2873–2879. PubMed

Bayle-Weisgerber C, Lemercier N, Teillet F, Asselain B, Gout M, Schweisguth O.. Hodgkin’s disease in children. Results of therapy in a mixed group of 178 clinical and pathologically staged patients over 13 years. Cancer 1984;54:215–222. PubMed

Bizet P, Saias-Magnan J, Jouve E, Grillo JM, Karsenty G, Metzler-Guillemain C, Perrin J.. Sperm cryopreservation before cancer treatment: a 15-year monocentric experience. Reprod Biomed Online 2012;24:321–330. PubMed

Björndahl L, Barratt CLR, Mortimer D, Jouannet P.. “How to count sperm properly”: checklist for acceptability of studies based on human semen analysis. Hum Reprod 2016;31:227–232. PubMed

Bordallo MA, Guimarães MM, Pessoa CH, Carriço MK, Dimetz T, Gazolla HM, Dobbin J, Castilho IA.. Decreased serum inhibin B/FSH ratio as a marker of Sertoli cell function in male survivors after chemotherapy in childhood and adolescence. J Pediatr Endocrinol Metab 2004;17:879–887. PubMed

Brice P, de Kerviler E, Friedberg JW.. Classical Hodgkin lymphoma. Lancet 2021;398:1518–1527. PubMed

Brignardello E, Felicetti F, Castiglione A, Nervo A, Biasin E, Ciccone G, Fagioli F, Corrias A.. Gonadal status in long-term male survivors of childhood cancer. J Cancer Res Clin Oncol 2016;142:1127–1132. PubMed PMC

Brougham MFH, Kelnar CJH, Sharpe RM, Wallace WHB.. Male fertility following childhood cancer: current concepts and future therapies. Asian J Androl 2003;5:325–337. PubMed

Caponecchia L, Cimino G, Sacchetto R, Fiori C, Sebastianelli A, Salacone P, Marcucci I, Tomassini S, Rago R.. Do malignant diseases affect semen quality? Sperm parameters of men with cancers. Andrologia 2016;48:333–340. PubMed

Cooper TG, Noonan E, von ES, Auger J, Baker HG, Behre HM, Haugen TB, Kruger T, Wang C, Mbizvo MT. et al. World Health Organization reference values for human semen characteristics. Hum Reprod Update 2010;16:231–245. PubMed

Crofton PM, Evans AE, Groome NP, Taylor MR, Holland CV, Kelnar CJ.. Inhibin B in boys from birth to adulthood: relationship with age, pubertal stage, FSH and testosterone. Clin Endocrinol (Oxf) 2002;56:215–221. PubMed

da Cunha MF, Meistrich ML, Fuller LM, Cundiff JH, Hagemeister FB, Velasquez WS, McLaughlin P, Riggs SA, Cabanillas FF, Salvador PG.. Recovery of spermatogenesis after treatment for Hodgkin’s disease: limiting dose of MOPP chemotherapy. J Clin Oncol 1984;2:571–577. PubMed

Daudin M, Rives N, Walschaerts M, Drouineaud V, Szerman E, Koscinski I, Eustache F, Saïas-Magnan J, Papaxanthos-Roche A, Cabry-Goubet R. et al. Sperm cryopreservation in adolescents and young adults with cancer: results of the French National Sperm Banking Network (CECOS). Fertil Steril 2015;103:478–486.e1. PubMed

Dempke WCM, Zielinski R, Winkler C, Silberman S, Reuther S, Priebe W.. Anthracycline-induced cardiotoxicity—are we about to clear this hurdle? Eur J Cancer 2023;185:94–104. PubMed

Drechsel K, Pilon M, Stoutjesdijk F, Meivis S, Schoonmade LJ, Wallace W, van Dulmen-den Broeder E, Beishuizen A, Kaspers G, Broer S. et al. Reproductive ability in survivors of childhood, adolescent and young adult Hodgkin lymphoma: a review. Hum Reprod Update 2023;29:486–517. PubMed PMC

Drechsel KCE, Broer SL, Stoutjesdijk FS, van Dulmen-den Broeder E, Beishuizen A, Wallace WH, Körholz D, Mauz-Körholz C, Hasenclever D, Cepelova M. et al. The impact of treatment for childhood classical Hodgkin lymphoma according to the EuroNet-PHL-C2 protocol on serum anti-Müllerian hormone. Hum Reprod 2024;39:1701–1711. PubMed PMC

European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL). Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescent: EuroNet-PHL-C2. 2015. https://classic.clinicaltrials.gov/ct2/show/NCT02684708 (26 July 2024, date last accessed).

Felicetti F, Castiglione A, Biasin E, Fortunati N, Dionisi-Vici M, Matarazzo P, Ciccone G, Fagioli F, Brignardello E.. Effects of treatments on gonadal function in long-term survivors of pediatric hematologic malignancies: a cohort study. Pediatr Blood Cancer 2020;67:e28709. PubMed

Franchimont P, Millet D, Vendrely E, Letawe J, Legros JJ, Netter A.. Relationship between spermatogenesis and serum gonadotropin levels in azoospermia and oligospermia. J Clin Endocrinol Metab 1972;34:1003–1008. PubMed

Gaml-Sørensen A, Thomsen AH, Tøttenborg SS, Brix N, Hougaard KS, Toft G, Håberg SE, Myrskylä M, Bonde JP, Ramlau-Hansen CH.. Maternal pre-pregnancy BMI and reproductive health in adult sons: a study in the Danish National Birth Cohort. Hum Reprod 2024;39:219–231. PubMed PMC

Green DM, Nolan VG, Goodman PJ, Whitton JA, Srivastava D, Leisenring WM, Neglia JP, Sklar CA, Kaste SC, Hudson MM et al.The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2014;61:53–67. PubMed PMC

Goossens E, Jahnukainen K, Mitchell RT, Van Pelt AMM, Pennings G, Rives N, Poels J, Wyns C, Lane S, Rodriguez-Wallberg KA. et al. Fertility preservation in boys: recent developments and new insights. Hum Reprod Open 2020;2020:hoaa016. PubMed PMC

Hjalgrim H, Jarrett RF.. Epidemiology of Hodgkin lymphoma. In: Engert A, Younes A, (eds). Hodgkin Lymphoma: A Comprehensive Overview. Switzerland: Springer International Publishing, 2020, 3–23. https://doi.org/10.1007/978-3-030-32482-7_1.

Hobbie WL, Ginsberg JP, Ogle SK, Carlson CA, Meadows AT.. Fertility in males treated for Hodgkins disease with COPP/ABV hybrid. Pediatr Blood Cancer 2005;44:193–196. PubMed

Howell SJ, Shalet SM.. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr 2005;(34):12–17. PubMed

IBM Corp. IBM SPSS Statistics for Windows, Version 28.0. Armonk, NY: IBM Corp, 2021.

Kelsey TW, McConville L, Edgar AB, Ungurianu AI, Mitchell RT, Anderson RA, Wallace WHB.. Follicle stimulating hormone is an accurate predictor of azoospermia in childhood cancer survivors. PLoS One 2017;12:e0181377. PubMed PMC

Kelsey TW, Miles A, Mitchell RT, Anderson RA, Wallace WH.. A normative model of serum Inhibin B in young males. PLoS One 2016;11:e0153843. PubMed PMC

Khanehzad M, Abbaszadeh R, Holakuyee M, Modarressi MH, Nourashrafeddin SM.. FSH regulates RA signaling to commit spermatogonia into differentiation pathway and meiosis. Reprod Biol Endocrinol 2021;19:4. PubMed PMC

Laddaga FE, Masciopinto P, Nardelli C, Vacca MP, Masciandaro P, Arcuti E, Cicinelli E, Specchia G, Musto P, Gaudio F.. In male Hodgkin lymphoma patients, impaired fertility may be improved by non-gonadotoxic therapy. Br J Haematol 2021;196:110–115. PubMed

Masliukaite I, Ntemou E, Feijen EAM, van de Wetering M, Meissner A, Soufan AT, Repping S, Kremer LMC, Jahnukainen K, Goossens E. et al. Childhood cancer and hematological disorders negatively affect spermatogonial quantity at diagnosis: a retrospective study of a male fertility preservation cohort. Hum Reprod 2023;38:359–370. doi: 10.1093/humrep/dead004. PubMed DOI PMC

Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M. et al. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol 2022;23:125–137. PubMed PMC

Meachem SJ, Nieschlag E, Simoni M.. Inhibin B in male reproduction: pathophysiology and clinical relevance. Eur J Endocrinol 2001;145:561–571. PubMed

Meistrich ML. Effects of chemotherapy and radiotherapy on spermatogenesis in humans. Fertil Steril 2013;100:1180–1186. PubMed PMC

Miles AE, Kelsey T, Wallace H.. A normative model of Inhibin B in young males. Maturitas 2015;81:128. PubMed PMC

Mulder RL, Font-Gonzalez A, Green DM, Loeffen EAH, Hudson MM, Loonen J, Yu R, Ginsberg JP, Mitchell RT, Byrne J. et al.; PanCareLIFE Consortium. Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2021;22:e57–e67. PubMed

Müller J. Disturbance of pubertal development after cancer treatment. Best Pract Res Clin Endocrinol Metab 2002;16:91–103. PubMed

Ortin TT, Shostak CA, Donaldson SS.. Gonadal status and reproductive function following treatment for Hodgkin’s disease in childhood: the Stanford experience. Int J Radiat Oncol Biol Phys 1990;19:873–880. PubMed

Pennisi AJ, Grushkin CM, Lieberman E.. Gonadal function in children with nephrosis treated with cyclophosphamide. Am J Dis Child 1975;129:315–318. PubMed

Pierik FH, Burdorf A, de Jong FH, Weber RF.. Inhibin B: a novel marker of spermatogenesis. Ann Med 2003;35:12–20. PubMed

Ragni G, Bestetti O, Santoro A, Viviani S, Di Pietro R, De Lauretis L.. Evaluation of semen and pituitary gonadotropin function in men with untreated Hodgkin’s disease. Fertil Steril 1985;43:927–930. PubMed

Raivio T, Saukkonen S, Jääskeläinen J, Komulainen J, Dunkel L.. Signaling between the pituitary gland and the testes: inverse relationship between serum FSH and inhibin B concentrations in boys in early puberty. Eur J Endocrinol 2000;142:150–156. PubMed

Romerius P, Ståhl O, Moëll C, Relander T, Cavallin-Ståhl E, Wiebe T, Giwercman YL, Giwercman A, Moe C, Wiebe T. et al. High risk of azoospermia in men treated for childhood cancer. Int J Androl 2010;34:69–76. PubMed

Rueffer U, Breuer K, Josting A, Lathan B, Sieber M, Manzke O, Grotenhermen F-J, Tesch H, Bredenfeld H, Koch P. et al. Male gonadal dysfunction in patients with Hodgkin’s disease prior to treatment. Ann Oncol 2001;12:1307–1311. PubMed

Santi D, Crépieux P, Reiter E, Spaggiari G, Brigante G, Casarini L, Rochira V, Simoni M.. Follicle-stimulating hormone (FSH) action on spermatogenesis: a focus on physiological and therapeutic roles. J Clin Med 2020;9:1014. PubMed PMC

Schaapveld M, Aleman BMP, Eggermond AM, Van Janus CPM, Krol ADG, Maazen RWM, Van Der Roesink J, Raemaekers JMM, Boer JP, De Zijlstra JM. et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med 2015;373:2499–2511. PubMed

Schoor RA, Elhanbly S, Niederberger CS, Ross LS.. The role of testicular biopsy in the modern management of male infertility. J Urol 2002;167:197–200. PubMed

Sherins RJ, Olweny CLM, Ziegler JL.. Gynecomastia and gonadal fysfunction in adolescent boys treated with combination chemotherapy for Hodgkin’s disease. N Engl J Med 1978;299:12–16. PubMed

Sieniawski M, Reineke T, Josting A, Nogova L, Behringer K, Halbsguth T, Fuchs M, Diehl V, Engert A.. Assessment of male fertility in patients with Hodgkin’s lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol 2008;19:1795–1801. PubMed

Stukenborg J-B, Jahnukainen K, Hutka M, Mitchell RT.. Cancer treatment in childhood and testicular function: the importance of the somatic environment. Endocr Connect 2018;7:R69–R87. PubMed PMC

Tal R, Botchan A, Hauser R, Yogev L, Paz G, Yavetz H.. Follow-up of sperm concentration and motility in patients with lymphoma. Hum Reprod 2000;15:1985–1988. PubMed

van Casteren NJ, Dohle GR Ph D, Romijn JC, van Casteren NJ, Dohle GR, Romijn JC, de Muinck Keizer-Schrama SMPF, Weber RFA, van den Heuvel-Eibrink MM.. Semen cryopreservation in pubertal boys before gonadotoxic treatment and the role of endocrinologic evaluation in predicting sperm yield. Fertil Steril 2008;90:1119–1125. PubMed

Wang Y, Ronckers CM, Leeuwen FE, van Moskowitz CS, Leisenring W, Armstrong GT, Vathaire F D, Hudson MM, Kuehni CE, Arnold MA. et al.; International Consortium for Pooled Studies on Subsequent Malignancies after Childhood and Adolescent Cancer. Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer. Nat Med 2023;29:2268–2277. PubMed PMC

Weinbauer GF, Luetjens CM, Simoni M, Nieschlag E.. Physiology of testicular function. In: Nieschlag E, Behre HM, Nieschlag S (eds). Andrology: Male Reproductive Health and Dysfunction. Berlin Heidelberg: Springer, 2010, 11–59.

Zaletel LZ, Bratanic N, Jereb B.. Gonadal function in patients treated for Hodgkin’s disease in childhood. Radiol Oncol 2010;44:187–193. PubMed PMC